LUNGevity FOUNDATION

FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2025 AND 2024

LUNGevity FOUNDATION

YEARS ENDED JUNE 30, 2025 AND 2024

CONTENTS

ORBA®
Accounting | Tax | Advisory

Independent Auditors' Report

Board of Directors
LUNGevity Foundation

Opinion

We have audited the accompanying financial statements of LUNGevity Foundation (a nonprofit organization), which comprise the statements of financial position as of June 30, 2025 and 2024, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of LUNGevity Foundation as of June 30, 2025 and 2024, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of LUNGevity Foundation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about LUNGevity Foundation's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of LUNGevity Foundation's internal control. Accordingly, no such opinion is expressed.

- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.

- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about LUNGevity Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Ostrow Reisin Berk & Abrams, Ltd.

November 25, 2025

LUNGevity FOUNDATION

STATEMENTS OF FINANCIAL POSITION

June 30,	**2025**	2024
ASSETS		
Cash	**$ 2,514,767**	$ 2,425,007
Grants receivable	**1,664,976**	688,802
Pledges receivable	**1,394,218**	2,339,076
Prepaid expenses	**442,970**	447,128
Security deposits	**24,523**	16,133
Property and equipment, net		6,666
Operating lease right-of-use assets	**127,679**	297,667
Total assets	**$ 6,169,133**	$ 6,220,479
LIABILITIES AND NET ASSETS		
Liabilities:		
Accounts payable	**$ 179,707**	$ 135,400
Accrued payroll and vacation	**459,628**	245,548
Grants payable	**100,000**	
Funds due to other organization(s)	**86,528**	
Operating lease liabilities	**130,872**	309,244
Total liabilities	**956,735**	690,192
Net assets:		
Without donor restrictions	**1,125,185**	512,643
With donor restrictions	**4,087,213**	5,017,644
Total net assets	**5,212,398**	5,530,287
Total liabilities and net assets	**$ 6,169,133**	$ 6,220,479

See notes to financial statements.

LUNGevity FOUNDATION

STATEMENTS OF ACTIVITIES

Years ended June 30,	2025			2024		
	Without donor restrictions	**With donor restrictions**	**Total**	Without donor restrictions	With donor restrictions	Total
Revenues:						
Contributions and grants	**$ 9,400,815**	**$ 3,225,650**	**$ 12,626,465**	$ 8,285,908	$ 4,003,128	$ 12,289,036
Contributed goods and services	**500**		**500**	113,301		113,301
Special events and other fundraisers:						
Gross revenue	**1,991,667**	**100,000**	**2,091,667**	1,942,133		1,942,133
Costs of direct benefits to donors	**(517,320)**		**(517,320)**	(524,563)		(524,563)
Net investment income (loss)	**33,896**		**33,896**	(831)		(831)
Net assets released from restrictions	**4,256,081**	**(4,256,081)**		3,128,995	(3,128,995)	
Total revenues	**15,165,639**	**(930,431)**	**14,235,208**	12,944,943	874,133	13,819,076
Expenses:						
Program services	**12,385,425**		**12,385,425**	13,773,611		13,773,611
Management and general	**688,109**		**688,109**	924,950		924,950
Fundraising	**1,479,563**		**1,479,563**	1,271,517		1,271,517
Total expenses	**14,553,097**		**14,553,097**	15,970,078		15,970,078
Change in net assets	**612,542**	**(930,431)**	**(317,889)**	(3,025,135)	874,133	(2,151,002)
Net assets:						
Beginning of year	**512,643**	**5,017,644**	**5,530,287**	3,537,778	4,143,511	7,681,289
End of year	**$ 1,125,185**	**$ 4,087,213**	**$ 5,212,398**	$ 512,643	$ 5,017,644	$ 5,530,287

See notes to financial statements.

LUNGevity FOUNDATION

STATEMENTS OF FUNCTIONAL EXPENSES

Year ended June 30, 2025	Program services							Costs of	
	Support services	Improving access to care	Patient and public education	Research	Total	Management and general	Fundraising	Costs of direct benefits to donors	Total
Advertising and marketing	$ 2,843	$ 14,726	$ 198,208		$ 215,777		$ 22,624	$ 10,134	$ 248,535
Depreciation and amortization	793	955	2,211	$ 625	4,584	$ 982	1,100		6,666
Grants		150,579		4,108,540	4,259,119				4,259,119
Meetings and events	427,825	259,145	116,640	159,684	963,294	765	37,421	482,661	1,484,141
Occupancy	33,051	39,805	92,112	26,050	191,018	25,063	45,837		261,918
Office expenses	29,477	68,251	195,011	29,705	322,444	16,048	54,081	23,263	415,836
Professional fees	50,604	616,724	230,056	351,750	1,249,134	10,050	74,351	1,262	1,334,797
Salaries and personnel costs	810,926	976,642	2,260,005	639,155	4,686,728	614,919	1,124,638		6,426,285
Website content licensing and other software fees	27,663	41,598	379,836	44,230	493,327	20,282	119,511		633,120
Total expenses	1,383,182	2,168,425	3,474,079	5,359,739	12,385,425	688,109	1,479,563	517,320	15,070,417
Less expenses included with revenues on the statements of activities								(517,320)	(517,320)
Total expenses included in the expenses section on the statements of activities	$ 1,383,182	$ 2,168,425	$ 3,474,079	$ 5,359,739	$ 12,385,425	$ 688,109	$ 1,479,563	$ -	$ 14,553,097

See notes to financial statements.

LUNGevity FOUNDATION

STATEMENTS OF FUNCTIONAL EXPENSES (CONTINUED)

Year ended June 30, 2024	Program services							Costs of direct benefits to donors	
	Support services	Improving access to care	Patient and public education	Research	Total	Management and general	Fundraising		Total
Advertising and marketing	$ 2,666	$ 180	$ 1,052,600	$ 388	$ 1,055,834		$ 79,414	$ 27,928	$ 1,163,176
Depreciation and amortization	1,167	1,957	2,446	1,164	6,734	$ 1,005	1,168		8,907
Grants		121,730		3,175,267	3,296,997				3,296,997
Meetings and events	338,624	216,633	121,042	138,357	814,656	36,139	27,247	454,753	1,332,795
Occupancy	35,561	59,621	74,420	35,186	204,788	30,661	35,629		271,078
Office expenses	126,507	118,814	198,871	27,474	471,666	15,327	36,973	27,924	551,890
Professional fees	118,279	462,693	979,388	526,026	2,086,386	9,818	44,505	13,958	2,154,667
Salaries and personnel costs	941,352	1,578,133	1,973,018	938,744	5,431,247	810,652	944,369		7,186,268
Website content licensing and other software fees	18,972	31,816	311,263	43,252	405,303	21,348	102,212		528,863
Total expenses	1,583,128	2,591,577	4,713,048	4,885,858	13,773,611	924,950	1,271,517	524,563	16,494,641
Less expenses included with revenues on the statements of activities								(524,563)	(524,563)
Total expenses included in the expenses section on the statements of activities	$ 1,583,128	$ 2,591,577	$ 4,713,048	$ 4,885,858	$ 13,773,611	$ 924,950	$ 1,271,517	$ -	$ 15,970,078

See notes to financial statements.

LUNGevity FOUNDATION

STATEMENTS OF CASH FLOWS

Years ended June 30,	2025	2024
Cash flows from operating activities:		
Change in net assets	**$ (317,889)**	$ (2,151,002)
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:		
Depreciation and amortization	**6,666**	8,907
Amortization of operating lease right-of-use assets	**237,514**	240,518
(Increase) decrease in operating assets:		
Grants receivable	**(976,174)**	(81,999)
Pledges receivable	**944,858**	(457,197)
Prepaid expenses	**4,158**	6,274
Security deposits	**(8,390)**	
Increase (decrease) in operating liabilities:		
Accounts payable	**44,307**	(98,484)
Accrued payroll and vacation	**214,080**	(48,217)
Grants payable	**100,000**	
Funds due to other organization(s)	**86,528**	
Operating lease liabilities	**(245,898)**	(241,841)
Net cash provided by (used in) operating activities	**89,760**	(2,823,041)
Net increase (decrease) in cash	**89,760**	(2,823,041)
Cash, beginning of year	**2,425,007**	5,248,048
Cash, end of year	**$ 2,514,767**	$ 2,425,007
Supplemental cash flows information related to leases is as follows:		
Operating lease right-of-use asset obtained in exchange for operating lease liability	**$ 67,526**	
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows from operating leases	**$ 267,535**	$ 270,774

See notes to financial statements.

1. Organization and purpose

LUNGevity Foundation (the Foundation), a leading lung cancer organization, is focused on transforming what it means to be diagnosed and live with lung cancer. The Foundation seeks to make an immediate impact on quality of life and survivorship for everyone touched by the disease – while promoting health equity by addressing disparities throughout the care continuum.

- Through research, the Foundation funds promising projects that focus on detecting lung cancer earlier, when it is most treatable. The Foundation also advances research into new treatments to help people live longer, healthier lives, while prioritizing a diverse and innovative pipeline of researchers who will drive the future of lung cancer care.

- Through advocacy, the Foundation fosters collaborations to ensure all people have access to screening, biomarker testing, and treatment breakthroughs.

- Through community, the Foundation educates, supports, and connects people affected by lung cancer so that they can get the best healthcare and live longer and better lives.

Comprehensive resources include a medically-vetted and patient-centric website, Patient Gateways, for specific types of lung cancer, a toll-free HELPLine for personalized support, and international survivor conferences. All these programs are designed to help the Foundation achieve its vision – a world where no one dies of lung cancer.

2. Summary of significant accounting policies

The significant accounting policies of the Foundation are summarized below:

Basis of accounting:

The Foundation's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.

2. Summary of significant accounting policies (continued)

Basis of presentation:

The Foundation is required to report information regarding its financial position and activities in two classes of net assets: Without donor restrictions and with donor restrictions.

> **Net assets without donor restrictions** - Net assets available to finance the general operations of the Foundation. The only limits on the use of net assets without donor restrictions are the broad limits resulting from the nature of the Foundation and the environment in which it operates.
>
> **Net assets with donor restrictions** - Net assets subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such that they will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that the resources be maintained in perpetuity. The Foundation reports contributions and grants restricted by donors as increases in net assets without donor restrictions if the restrictions expire (that is, when a stipulated time restriction ends or purpose restriction is accomplished) in the same reporting period in which the revenue is recognized. All other donor-restricted contributions and grants are reported as increases in net assets with donor restrictions, depending on the nature of the restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as net assets released from restrictions.

Contributions and grants:

Contributions and grants are recognized when cash or an unconditional promise to give is received. Conditional promises to give are not recognized until the conditions on which they depend have been substantially met.

Grants receivable:

Grants receivable are primarily comprised of amounts due from pharmaceutical companies that contribute to the Foundation's initiatives. Grants receivable are stated at the amount management expects to collect from the outstanding balances. Grants receivable are due in less than one year. The Foundation estimates an allowance for doubtful accounts based on an analysis of specific account history and experience. It is the Foundation's policy to charge off uncollectible grants receivable when management determines that the receivable will not be collected. Management believes that all grants receivable as of June 30, 2025 and 2024 are fully collectible; therefore, no allowance for doubtful accounts was recorded.

2. Summary of significant accounting policies (continued)

Pledges receivable:

Pledges receivable are primarily composed of amounts due from individual donors who commit multi-year contributions to support the Foundation's overall mission. Pledges receivable are stated at the amount management expects to collect from outstanding balances. Pledges receivable consist of unconditional promises to give at June 30, 2025 and 2024. Pledges receivable due in more than one year were discounted using a risk-adjusted rate of return (4.74% as of June 30, 2025 and 2024) to reflect the present value of the receivables. Amortization of the discount is included in contributions and grants revenue. The Foundation estimates an allowance for doubtful accounts based on an analysis of specific account history and experience. It is the Foundation's policy to charge off uncollectible grants receivable when management determines that the receivable will not be collected. Management believes that all pledges receivable as of June 30, 2025 and 2024 are fully collectible; therefore, no allowance for doubtful accounts was recorded.

June 30,	**2025**	2024
Pledges receivable due in less than one year	**$ 609,750**	$ 844,429
Pledges receivable due in one to five years	**925,000**	1,775,000
Total pledges receivable, gross	**1,534,750**	2,619,429
Discount to net present value	**(140,532)**	(280,353)
Total pledges receivable	**$ 1,394,218**	$ 2,339,076

Property and equipment:

Property and equipment are stated at cost or, if donated, at fair value at the date of donation. Depreciation of equipment and computer software and website is provided over the estimated life of the assets (ranging from 3 to 7 years) using the straight-line method. Amortization of leasehold improvements is provided ratably over the lesser of the term of the lease or the estimated life of the improvements (typically 5 years). Additions over $1,000 are capitalized while replacements, maintenance and repairs which do not improve or extend the lives of the respective assets are expensed.

2. Summary of significant accounting policies (continued)

Asset impairment:

Management reviews the carrying values of property and equipment and operating lease right-of-use assets for impairment whenever events or circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. When considered impaired, an impairment loss is recognized to the extent the carrying value exceeds the fair value of the asset. There were no indicators of asset impairment during the years ended June 30, 2025 and 2024.

Grants payable:

Grants payable represents amounts of funding awarded during the year but not yet paid by year-end and are payable within one year of the statements of financial position date.

Funds due to other organization(s):

Funds due to other organization(s) include amounts received by the Foundation on behalf of other not-for-profit organizations in which the Foundation is acting as an agent and does not have variance power to determine how those funds could be spent.

Leases:

The Foundation determines whether a contract is a lease at the contract's inception. Identified leases are subsequently measured, classified, and recognized at lease commencement as either a finance lease or an operating lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease based on the estimated present value of lease payments to be made over the lease term. The Foundation's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Foundation will exercise the option. The lease payments are discounted to present value using a discount rate based on a term commensurate with the lease terms at the lease commencement date. The Foundation used an incremental borrowing rate for the office leases. The portion of payments on operating lease liabilities related to interest, along with the amortization of the related right-of-use assets, is recognized as operating lease cost. Operating lease cost is recognized on a straight-line basis over the lease term.

Advertising:

Advertising costs are expensed when incurred. Total advertising costs were $90,496 and $125,654 for the years ended June 30, 2025 and 2024, respectively.

2. Summary of significant accounting policies (continued)

Expense allocation:

The costs of program and supporting activities have been summarized on a functional basis in the statements of activities. The statements of functional expenses present the natural classification of expenses by function. Operating expenses identified with a functional area are charged directly to that area and where those expenses affect more than one area, they are allocated on a reasonable basis that is consistently applied. These expenses, allocated on the basis of estimates of time and effort, were salaries and personnel costs, meetings and events, office expenses and depreciation and amortization. Occupancy is allocated based on estimates of square footage.

Use of estimates:

The preparation of financial statements in accordance accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures in the financial statements. Accordingly, actual results could differ from those estimates.

Subsequent events:

Management of the Foundation has reviewed and evaluated subsequent events through November 25, 2025, the date the financial statements were available to be issued.

3. Liquidity and availability

The Foundation regularly monitors liquidity required to meet its operating needs and other contractual commitments by reviewing projections of anticipated annual revenue and expenses monthly as well as by reviewing monthly budget-to-actual reports.

The following represents the Foundation's financial assets available to meet general expenditures within one year as of June 30, 2025 and 2024:

June 30,	**2025**	2024
Financial assets at year-end:		
Cash	**$ 2,514,767**	$ 2,425,007
Grants receivable	**1,664,976**	688,802
Pledges receivable	**1,394,218**	2,339,076
Total financial assets	**5,573,961**	5,452,885
Less amounts not available to be used within one year:		
Funds due to other organization(s)	**86,528**	
Pledges receivable due in one to five years, net	**784,468**	1,494,647
Purpose restricted net assets	**1,028,019**	1,989,766
Total amounts not available to be used within one year	**1,899,015**	3,484,413
Financial assets available to meet general expenditures within one year	**$ 3,674,946**	$ 1,968,472

4. Property and equipment

The components of property and equipment were as follows:

June 30, 2024		
Equipment	$	22,780
Computer software and website		55,705
Leasehold improvements		35,026
		113,511
Accumulated depreciation and amortization		(106,845)
Property and equipment, net	$	6,666

Property and equipment were fully depreciated and written-off during the year ended June 30, 2025.

5. Revenue from contracts with customers

The Foundation held one fundraising event during each of the years ended June 30, 2025 and 2024. In exchange for the registration fee, participants receive various direct benefits, including food and beverages. The estimated value of direct benefits provided is recognized as revenue from contracts with customers at a point in time when the event took place. Payment is due as of the date when participants confirm their registration. The Foundation recognized $100,000 and $62,500 of special events and other fundraisers revenue from contracts with customers during the years ended June 30, 2025 and 2024, respectively, which is included in special events and other fundraisers revenue on the statements of activities. There were no receivables related to contracts with customers as of June 30, 2025, 2024 and 2023. There were also no contract assets or contract liabilities at June 30, 2025, 2024 and 2023.

6. Contributed goods and services

Contributed goods and services are reported at fair value in the financial statements when the services create or enhance non-financial assets or require specialized skills provided by individuals possessing those skills and are services which would be typically purchased if not provided by donation.

6. Contributed goods and services (continued)

The Foundation receives donated services from unpaid volunteers who assist in its fundraising events and programs by reviewing research proposals. In addition, many individuals volunteer their time and perform a variety of tasks that assist the Foundation. With the exception of the services noted in the following paragraph, none of these amounts have been recognized in the statements of activities because the criteria for recognition have not been met.

The Foundation receives various forms of contributed goods and services. Contributed goods and services are reported at their estimated fair value and reported as revenue without donor restrictions when received and reported as expenses when utilized. Contributed goods are not sold and goods and services are only used by the Foundation for program use. There were no donor restrictions for contributed goods and services recognized during the years ended June 30, 2025 and 2024.

Contributed goods and services consisted of the following for the year ended June 30, 2025:

Non-financial contributions category	**Type of contributions**	**Valuation**	**Year ended June 30, 2025**
Food and non-food items	**Food and beverage and other costs related to meetings and events**	**Third-party estimates using costs of similar goods in like circumstances**	**$ 500**

Contributed goods and services consisted of the following for the year ended June 30, 2024:

Non-financial contributions category	Type of contributions	Valuation	Year ended June 30, 2024
Food and non-food items	Food and beverage and other costs related to meetings and events	Third-party estimates using costs of similar goods in like circumstances	$ 43,601
In-kind services	Professional services including advertising and marketing and research provided by the Foundation's Scientific Advisory Board	Standard industry pricing for similar services	69,700
Total contributed goods and services			$ 113,301

7. Net assets with donor restrictions

Net assets with donor restrictions are restricted for the following purpose and time restrictions as of June 30, 2025 and 2024:

June 30,	2025	2024
Purpose restrictions:		
Celebration of Hope gala	**$ 84,862**	
Patient and advocate support		$ 95,000
Patient and public education	**112,500**	
Public policy initiatives		75,000
Research:		
ALK Project Fund		437,500
Clinical research	**748,174**	1,167,190
Patient FoRCe	**82,483**	215,076
Total net assets with purpose restrictions	**1,028,019**	1,989,766
Time restrictions:		
Grants receivable	**1,664,976**	688,802
Pledges receivable	**1,394,218**	2,339,076
Total net assets with time restrictions	**3,059,194**	3,027,878
Total net assets with donor restrictions	**$ 4,087,213**	$ 5,017,644

7. Net assets with donor restrictions (continued)

During the years ended June 30, 2025 and 2024, net assets were released from donor restrictions by incurring expenses satisfying the following purpose restrictions specified by donors and satisfying time restrictions:

Years ended June 30,	**2025**	2024
Purpose restrictions:		
Celebration of Hope gala	**$ 15,138**	
Improving access to care		$ 721,873
Patient and advocate support	**95,000**	91,625
Patient and public education	**125,000**	
Public policy initiatives	**75,000**	
Research:		
ALK Project Fund	**437,500**	437,500
Clinical research	**1,167,190**	543,067
Patient FoRCe	**707,593**	185,324
Total net assets released from purpose restrictions	**2,622,421**	1,979,389
Time restrictions:		
Grants receivable	**688,802**	606,803
Pledges receivable	**944,858**	542,803
Total net assets released from time restrictions	**1,633,660**	1,149,606
Total net assets released from donor restrictions	**$ 4,256,081**	$ 3,128,995

8. Tax status

The Foundation is a tax-exempt organization as described in Section 501(c)(3) of the Internal Revenue Code (the Code) and is exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. In addition, the Internal Revenue Service (IRS) has determined that the Foundation is not a private foundation within the meaning of Section 509(a) of the Code. Management has determined that the Foundation was not required to record a liability related to uncertain tax positions as of June 30, 2025 and 2024.

9. Conditional promises to receive

The Foundation records revenue associated with conditional promises to receive when the conditions have been substantially met.

Conditional promises to receive consist of the following as of June 30, 2024:

June 30, 2024		
ALK Research Award	$	437,500
Early Detection Research Award		150,000
Non-Small Lung Cancer Research		500,000
Survivorship Summit and Celebration of Hope		60,000
Translational Research Immunotherapy		248,174
Total	$	1,395,674

All conditions were met for the conditional promises to receive and recognized as revenue during the year ended June 30, 2025. There were no conditional promises to receive as of June 30, 2025.

10. Conditional grant commitments

The Foundation funds requests for research award applications and issues research awards to medical investigators for pre-approved studies. The Foundation's Scientific Advisory Board reviews multi-year research awards annually through progress reports. The Foundation reserves the right to terminate future funding for a multi-year award if a progress report reflects unsatisfactory progress. As such, the Foundation is only committed to funding awards for the following year. As of June 30, 2025, future conditional research award commitments total approximately $2,553,000 for the year ending June 30, 2026 and $522,000 for the year ending June 30, 2027.

11. Leases

The Foundation leased office space in Chicago, Illinois through March 2025 and then entered into a new office lease through March 2027. The Foundation also leases office space in Bethesda, Maryland through November 2025. The leases include annual escalating payments and there are no renewal options. Lease payments are due monthly.

11. Leases (continued)

Operating lease cost was $260,894 and $269,452 for the years ended June 30, 2025 and 2024, respectively. The weighted-average discount rate for the operating leases during the years ended June 30, 2025 and 2024 was 6.55% and 5.25%, respectively, and the weighted-average remaining lease term as of June 30, 2025 and 2024 was 1.03 and 1.25 years, respectively.

Future payments on the operating leases are as follows:

Year ending June 30:	Amount
2026	$ 112,773
2027	28,753
Total undiscounted lease payments	141,526
Imputed interest	(10,654)
Total operating lease liabilities	$ 130,872

12. Retirement plan

The Foundation sponsors a 401(k) plan (the Plan) covering all employees who meet the eligibility requirements. The Foundation makes matching contributions to the Plan equal to 100% of the first 3% of employee deferrals and 50% of the next 2% of employee deferrals, up to a maximum of 4% of employee compensation for a calendar year. Contributions to the Plan were $142,561 and $154,040 for the years ended June 30, 2025 and 2024, respectively.

13. Concentration of credit risk

The Foundation maintains its cash in bank deposit accounts which, at times, may exceed federally-insured limits. The uninsured balance was approximately $2,252,000 and $2,126,000 as of June 30, 2025 and 2024, respectively. Management believes that the Foundation is not exposed to any significant credit risk on cash.

Credit risk for grants receivable was concentrated with two grantors accounting for approximately 58% of grants receivable as of June 30, 2025. Credit risk for grants receivable was concentrated with two grantors accounting for approximately 87% of grants receivable as of June 30, 2024. Pledges receivable as of June 30, 2025 and 2024 was concentrated with four donors, three of whom are Board members, accounting for 97% of pledges receivable.

13. Concentration of credit risk (continued)

One donor accounted for approximately 13% of total revenues for the year ended June 30, 2025. There were no revenue concentrations for the year ended June 30, 2024.

14. Related parties

Pledges receivable due from Board members as of June 30, 2025 and 2024 were $1,034,750 and $1,869,429, respectively.

The Foundation received contributions from board members during the years ended June 30, 2025 and 2024 of approximately $716,000 and $46,000, respectively.